Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure
- Conditions
- Chronic Heart Failure
- First Posted Date
- 2006-02-20
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 160
- Registration Number
- NCT00294086
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
- Conditions
- Recurrent Glioblastoma Multiforme (GBM)
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 231
- Registration Number
- NCT00290771
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1272
- Registration Number
- NCT00289978
- Locations
- 🇦🇺
The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
🇦🇺North Gosford Private Hospital, Burrabil Avenue, Suite 17, Gosford, Australia
🇦🇺Strategic Health Evaluators, Chatswood, Australia
Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
- Conditions
- Age-Related Macular Degeneration (ARMD)
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2008-06-19
- Lead Sponsor
- Novartis
- Registration Number
- NCT00288561
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients
- Conditions
- Kidney Diseases
- Interventions
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2011-05-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 94
- Registration Number
- NCT00284934
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids
- Conditions
- Adverse EffectsKidney Transplantation
- Interventions
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 7
- Registration Number
- NCT00284947
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
- Conditions
- Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)
- Interventions
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 88
- Registration Number
- NCT00284089
- Locations
- 🇯🇵
Novartis, Tokyo, Japan
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 151
- Registration Number
- NCT00284050
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2006-01-23
- Last Posted Date
- 2010-11-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 648
- Registration Number
- NCT00280540
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia
- Conditions
- Constipation and Dyspepsia
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Novartis
- Registration Number
- NCT00277550